| Tolerant | Intolerant | P-value |
---|---|---|---|
Treatment courses (n) | 142 | 104 | -- |
Baseline Characteristics | Â | Â | Â |
 Age (years (SD)) | 64.1 (12.5) | 66.7 (12.0) | 0.094 |
 Sex (n, % female) | 110 (77%) | 79 (73%) | 0.418 |
 Baseline FEV1 (% predicted mean (SD)) | 80.5 (23.0) | 76.4 (23.5) | 0.22 |
 Caucasian (n, %) | 88 (62%) | 61 (59%) | 0.694 |
 Asian (n, %) | 36 (25%) | 28 (27%) | 0.896 |
 Other ethnicity (non-Caucasian, non-Asian, n, %) | 18 (13%) | 15 (14%) | 0.835 |
 Body Mass Index (mean (SD)) | 21.5 (4.0) | 22.3 (5.4) | 0.121 |
 Fibrocavitary Disease (n, %) | 34 (24%) | 20 (19%) | 0.28 |
 Smear positive (n, %) | 28 (20%) | 37 (34%) | 0.009 |
 Charlson Comorbidity Index (mean (SD)) | 4.8 (3.2) | 6.1 (4.6) | 0.007 |
 Organ Transplant (n, %) | 2 (1.4%) | 7 (6.5%) | 0.064 |
 Liver Disease (n, %) | 2 (1.4%) | 8 (7%) | 0.032 |
 Chronic Kidney Disease Stage 3 or greater (n, %) | 6 (4%) | 6 (5.5%) | 0.798 |
 Immune Compromise, not HIV (n, %) | 24 (17%) | 21 (19%) | 0.622 |
 Diabetes (n, %) | 7 (5%) | 8 (8%) | 0.532 |
 Heart Failure (n, %) | 10 (7%) | 12 (11%) | 0.320 |
 Ocular Disease (n, %) | 27 (19%) | 22 (21%) | 0.800 |
 Connective Tissue Disease (n, %) | 12 (9%) | 15 (14%) | 0.203 |
 GERD (n, %) | 36 (25%) | 25 (24%) | 0.931 |
Disease Characteristics | Â | Â | Â |
 Macrolide sensitive (n, %) | 125 (88%) | 102 (94%) | 0.8721 |
 Daily therapy (n, %) | 109 (77%) | 85 (79%) | 0.816 |
 Inhaled amikacin (n, %) | 9 (6%) | 8 (7%) | 0.873 |
 Amikacin liposomal inhalation suspension (n, %) | 7 (5%) | 15 (14%) | 0.033 |
 Parenteral amikacin on initiation (n, %) | 8 (6%) | 8 (7%) | 0.932 |
Outcomes | Â | Â | Â |
 Mean treatment duration (months, range) | 21 (9–54) | 19 (0.5–55) | 0.572 |
 Culture positive at 6 months (n, %) | 37 (25%) | 45 (43%) | < 0.001 |
 Recurrence within 12 months (n, %) | 28 (20%) | 17 (24%) | 0.524 |
 Death from any cause (n, %) | 13 (9%) | 13 (12%) | 0.527 |